H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Enlivex Therapeutics to $12 from $15 and keeps a Buy rating on the shares. The new target reflects significantly lower operating expenses but also the impact of removal of the Allocetra oncology and graft-vs.-host disease indications from the valuation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENLV:
- Enlivex Therapeutics to reduce workforce by 50%
- Enlivex Therapeutics announces reprioritization plan
- Enlivex Therapeutics expects cash to fund operations through end of 2025
- Enlivex Therapeutics announces peer-reviewed publication on Allocetra
- Enlivex doses first patient under amended protocol of Phase II trial
